Adenosine Receptor: A Potential Drug Target for Cancer, Cardiovascular Disease and Neurodegenerative Disorders

Target Name: Adenosine receptor

NCBI ID: P5677

Adenosine receptor

Other Name(s): ADOR

Adenosine Receptor: A Potential Drug Target for Cancer, Cardiovascular Disease and Neurodegenerative Disorders

Adenosine receptor (nonspecified subtype), also known as ADOR, is a G protein-coupled receptor that is expressed in various tissues throughout the body. It plays a crucial role in cellular signaling, particularly in the regulation of inflammation and immune responses. The ADOR receptor has been identified as a potential drug target and is currently being studied as a potential therapeutic approach for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

ADOR is a G protein-coupled receptor, which means it is composed of a transmembrane protein that is connected to intracellular signaling pathways. The ADOR receptor is composed of two transmembrane subunits, which are held together by ionic bonds. The second transmembrane subunit contains a catalytic 伪-helices, which are responsible for the conformational changes that occur upon agonist binding. These changes in伪-helices are critical for the formation of the interconcerted action between the subunits and the intracellular signaling pathways.

Adenosine is a naturally occurring molecule that is produced by the body in response to stress, inflammation, or other stimuli. It is a small molecule that acts as an immunosuppressant, anti-inflammatory, and neuroprotective agent. Adenosine has been shown to play a crucial role in the regulation of cellular signaling pathways, including the regulation of inflammation and immune responses.

The ADOR receptor is involved in the regulation of various cellular signaling pathways, including the regulation of inflammation, cell signaling, and neurotransmission. It has been shown to play a role in the regulation of inflammation by modulating the activity of immune cells and promoting the production of anti-inflammatory cytokines.

The ADOR receptor is also involved in the regulation of cell signaling pathways, including the regulation of cell proliferation, differentiation, and survival. It has been shown to play a role in the regulation of cell signaling pathways by modulating the activity of various signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the Wnt signaling pathway.

The ADOR receptor is also involved in the regulation of neurotransmission, including the regulation of neurotransmitter release and receptor function. It has been shown to play a role in the regulation of neurotransmission by modulating the activity of various neurotransmitter receptors, including N-methyl-D-aspartate (NMDA) receptors and muscarinic acetylcholine receptors.

The ADOR receptor has been shown to be a potential drug target due to its involvement in various cellular signaling pathways and its role in the regulation of inflammation and immune responses. Several studies have shown that blocking the ADOR receptor can lead to therapeutic effects in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

For example, studies have shown that inhibition of the ADOR receptor can lead to therapeutic effects in cancer, particularly in breast cancer. In breast cancer, the ADOR receptor is often overexpressed, which can lead to the development of cancer cell stemness and the formation of cancer stem-derived tumors. Therefore, inhibition of the ADOR receptor has been shown to be a promising therapeutic approach for the treatment of breast cancer.

Another study has shown that inhibition of the ADOR receptor can lead to therapeutic effects in cardiovascular disease. The ADOR receptor has been shown to play a role in the regulation of blood pressure and cardiovascular risk. In cardiovascular disease, the ADOR receptor is often overexpressed, which can lead to the development of cardiovascular risk factors. Therefore, inhibition of the ADOR receptor has been shown to be a promising therapeutic approach for the treatment of cardiovascular disease.

A third study has shown that inhibition of the ADOR receptor can lead to therapeutic effects in neurodegenerative disorders. The ADOR receptor has been shown to play

Protein Name: Adenosine Receptor (nonspecified Subtype)

The "Adenosine receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Adenosine receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets